Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience.

about

When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies.Bortezomib treatment for severe refractory anti-NMDA receptor encephalitis.

P2860

Q49280339-78799F80-4F81-41C3-BE68-48FCE5B89222 Q55407957-A863C0DF-79E4-49C1-9F35-E811FF788C6F

P2860

Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience.

Item

http://www.wikidata.org/entity/Q41657907

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience.

@en

type

Item

label

Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience.

@en

prefLabel

Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience.

@en

P1476

Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience.

@en

P2093

Anke Reinacher-Schick

http://www.w3.org/2001/XMLSchema#string

Christiane Schneider-Gold

http://www.w3.org/2001/XMLSchema#string

Gisa Ellrichmann

http://www.w3.org/2001/XMLSchema#string

Ralf Gold

http://www.w3.org/2001/XMLSchema#string

P2860

International consensus guidance for management of myasthenia gravis: Executive summary

Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society

Future perspectives in target-specific immunotherapies of myasthenia gravis

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

Bortezomib for refractory autoimmunity in pediatrics.

Proteasome inhibition with bortezomib depletes plasma cells and specific autoantibody production in primary thymic cell cultures from early-onset myasthenia gravis patients

The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus

Plasma cell development: from B-cell subsets to long-term survival niches.

Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis?

Proteasome inhibitors as experimental therapeutics of autoimmune diseases.

P304

339-341

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1756285617721093

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28966662

http://www.w3.org/2001/XMLSchema#string

P921

myasthenia gravis

P932

5607927

http://www.w3.org/2001/XMLSchema#string

Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience.

about

P2860

P2860

Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932